$NXRT

New Strong Sell Stocks for September 4th

DERM, HOPE and NXRT have been added to the Zacks Rank #5 (Strong Sell) List on September 4, 2025.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Sep 4, 2025, 12:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 5, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
New Strong Sell Stocks for September 4th — source image
Decision brief

The 30-second read

$NXRTNeutralMed
01

Why it matters

This rating change suggests increased bearish sentiment and potential for short-term price declines, influencing trading strategies.

02

Market read

The news indicates a bearish shift for these specific stocks, which could influence sector sentiment but has limited immediate impact on broader markets.

03

What to watch

Potential upcoming positive catalysts or sector-wide recovery signals that could offset current bearish ratings.

Timing: short-term (within 1 month)

Background

The stocks DERM, HOPE, and NXRT have been added to the Zacks Rank #5 (Strong Sell) list as of September 4, 2025, based on recent negative earnings revisions or fundamental concerns.

Company-level read

Ticker impact

$NXRTNeutralMedium confidence
Context

Moderately relevant due to neutral sentiment and moderate relevance score.

Expected impact

Potential further decline; expected downside of 3-5% over the next month.

Evidence & confidence

The neutral sentiment and recent downgrade suggest cautious outlook, but lack of strong negative sentiment limits high confidence.

$HOPENeutralMedium confidence
Context

Moderately relevant with neutral sentiment and similar relevance score.

Expected impact

Possible decline of 2-4% in the short term.

Evidence & confidence

The neutral sentiment and inclusion on the Strong Sell list imply potential downside, but absence of negative catalysts reduces certainty.

$DERMNeutralMedium confidence
Context

Moderately relevant with neutral sentiment; similar relevance score as others.

Expected impact

Anticipated decrease of approximately 3-6% over the coming weeks.

Evidence & confidence

The neutral sentiment combined with the Strong Sell designation suggests caution, though lack of negative news limits high confidence.

Market effects

Potential negative sentiment spreading across the real estate, life sciences, and finance sectors due to stock downgrades.

Limited regional impact; primarily affecting individual stocks and their sectors.

Minimal; these are specific stock ratings without broader global implications.

Counterpoint

Some analysts may argue that the inclusion on the Strong Sell list could be overreactive, and these stocks might experience a short-term bounce or stabilization.

Key entities

  • Zacks Equity Research

    Provider of stock research and ratings.

  • DERM

    A company in the relevant sector, currently rated as Strong Sell.

  • HOPE

    A company in the relevant sector, currently rated as Strong Sell.

  • NXRT

    A company in the relevant sector, currently rated as Strong Sell.

Related articles

$DERMMed

Journey Medical Corp (DERM): Results of Operations and Financial Condition

Journey Medical Corp (DERM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622742d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

$NXRTHighAI 8/10

NexPoint Residential Trust (NXRT) Q2 2026 Earnings Call Transcript

NexPoint Residential Trust (NXRT) reported Q2 2026 Core FFO of $16.9 million, or $0.66 per diluted share, down from $18.0 million, or $0.71, a year earlier. Full-year Core FFO guidance was lowered to a $2.45 midpoint. Total revenue rose to $64.6 million. Management cited higher interest expense headwinds from swap inflow changes and softer market revenue, especially Nashville.

$NXRTMed

NexPoint Residential Trust, Inc. Q2 2026 Earnings Call Summary

NexPoint Residential Trust, Inc. reported Q2 2026 earnings call updates. Management lowered full-year core FFO guidance, citing a higher forward SOFR curve that reduced projected swap inflows by about $14.6M. Same-store NOI decline was concentrated in Nashville (~85%). Leasing trade-outs turned positive in July. Guidance assumes a late-2026/2027 “clean inflection” with swap protection roll-off of ~$717.5M.

$NXRTMed

NEXPOINT RESIDENTIAL TRUST, INC. REPORTS SECOND QUARTER 2026 RESULTS

NexPoint Residential Trust (NYSE:NXRT) reported Q2 2026 results for the quarter ended June 30. Net loss attributable to common stockholders was $8.6M, with FFO $15.2M and AFFO $19.7M. Revenue rose to $64.6M. Occupancy was 93.5% and same-store revenue and NOI fell. The company deployed a $22.1M 10% fixed-rate DST bridge loan and paid a $0.53 dividend.

$NXRTMed

NexPoint Residential Trust, Inc. (NXRT): Results of Operations and Financial Condition

NexPoint Residential Trust, Inc. (NXRT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nxrt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 4 August 2026 | NYSE: NXRT EARNINGS SUPPLEMENT: SECOND QUARTER 2026 NEXPOINT RESIDENTIAL TRUST, INC. 300 CRESCENT COURT, SUITE 700 DALLAS, TX 75201 INVESTOR RELATIONS: KRISTEN GRIFFITH NXRT.NEXPOINT.COM NEXPOINT RESIDENTIAL T

$HOPEMed

Hope Bancorp shares climb after second-quarter revenue tops estimates

Hope Bancorp (NASDAQ:HOPE) shares rose about 5% premarket after its Q2 results. Adjusted EPS was $0.26, matching analyst forecasts. Revenue was $147.82 million versus $146.49 million expected. Net income rose to $33.0 million. Net interest income increased and net interest margin improved to 2.96%, with credit costs easing.